Postprandial Changes in Solubilizing Capacity of Human Intestinal Fluids for BCS Class II Drugs

被引:104
作者
Clarysse, Sarah [1 ]
Psachoulias, Dimitrios [2 ]
Brouwers, Joachim [1 ]
Tack, Jan [3 ]
Annaert, Pieter [1 ]
Duchateau, Guus [4 ]
Reppas, Christos [2 ]
Augustijns, Patrick [1 ]
机构
[1] Lab Pharmacotechnol & Biopharm, B-3000 Leuven, Belgium
[2] Univ Athens, Lab Biopharmaceut & Pharmacokinet, Athens 11528, Greece
[3] Univ Hosp Leuven, Dept Gastroenterol, Leuven, Belgium
[4] Unilever Res Labs, Bioavailabil & ADME Grp, Vlaardingen, Netherlands
关键词
human intestinal fluids; poorly water soluble drugs; postprandial; simulated intestinal fluid; solubilizing capacity; IN-VITRO LIPOLYSIS; DISSOLUTION MEDIA; INTRALUMINAL DRUG; SOLUBLE DRUGS; BIOAVAILABILITY; DIGESTION; BEHAVIOR; DANAZOL; LIPIDS; CHAIN;
D O I
10.1007/s11095-009-9857-7
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
To explore the effect of the nutritional state on the solubilizing properties of human intestinal fluids (HIF) on a time-after-food administration basis. HIF were collected in fractions of 30 min from five volunteers in the fasted, fed and fat-enriched fed state. In vitro solubility of five BCS class II drugs (danazol, diazepam, nifedipine, ketoconazole, indomethacin) was assessed in the intestinal fractions and simulated intestinal fluids. Solubilities in intestinal fractions were characterized by high time- and subject-dependent variability. For the non-ionized drugs, solubility in early intestinal fractions was higher in both fed states compared to the fasted state, and in the fat-enriched fed state compared to the fed state. Solubility in simulated intestinal fluids did not sufficiently predict the solubilizing capacity of the early postprandial phase. Solubility in HIF was shown to be determined by a complex interplay of various intraluminal parameters. For the ionized drugs, pH played a significant role for indomethacin (R (2) = 0.86); for the partly ionized ketoconazole other intraluminal parameters were also important. Solubilizing capacity of HIF in the fed state is strongly time-dependent. Intraluminal dissolution may, therefore, vary with drug arrival time in the small intestine and constitute a source of variability in intestinal drug absorption.
引用
收藏
页码:1456 / 1466
页数:11
相关论文
共 25 条
  • [1] Postprandial Changes in Solubilizing Capacity of Human Intestinal Fluids for BCS Class II Drugs
    Sarah Clarysse
    Dimitrios Psachoulias
    Joachim Brouwers
    Jan Tack
    Pieter Annaert
    Guus Duchateau
    Christos Reppas
    Patrick Augustijns
    Pharmaceutical Research, 2009, 26 : 1456 - 1466
  • [2] Understanding the Impact of Lipids on the Solubilizing Capacity of Human Intestinal Fluids
    Goovaerts, Brecht
    Brouwers, Joachim
    Vinarov, Zahari
    Braeckmans, Marlies
    Indulkar, Anura S.
    Marmol, Alvaro Lopez
    Borchardt, Thomas B.
    Tack, Jan
    Koziolek, Mirko
    Augustijns, Patrick
    MOLECULAR PHARMACEUTICS, 2024, 21 (12) : 6398 - 6410
  • [3] The apparent solubilizing capacity of simulated intestinal fluids for poorly water-soluble drugs
    Schwebel, Herve J.
    van Hoogevest, Peter
    Leigh, Mathew L. S.
    Kuentz, Martin
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2011, 16 (03) : 278 - 286
  • [4] Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models
    Dahlgren, David
    Sjogren, Erik
    Lennernas, Hans
    ADMET AND DMPK, 2020, 8 (04): : 375 - 390
  • [5] Prediction of positive food effect: Bioavailability enhancement of BCS class II drugs
    Raman, Siddarth
    Polli, James E.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 506 (1-2) : 110 - 115
  • [6] In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen
    Tsume, Yasuhiro
    Langguth, Peter
    Garcia-Arieta, Alfredo
    Amidon, Gordon L.
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2012, 33 (07) : 366 - 377
  • [7] Characterisation of colloidal structures and their solubilising potential for BCS class II drugs in fasted state simulated intestinal fluid
    Mckinnon, Zoe
    Khadra, Ibrahim
    Halbert, Gavin W.
    Batchelor, Hannah K.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 665
  • [8] In Vitro-in Vivo Correlation of the Effect of Supersaturation on the Intestinal Absorption of BCS Class 2 Drugs
    Higashino, Haruki
    Hasegawa, Tsubasa
    Yamamoto, Mari
    Matsui, Rie
    Masaoka, Yoshie
    Kataoka, Makoto
    Sakuma, Shinji
    Yamashita, Shinji
    MOLECULAR PHARMACEUTICS, 2014, 11 (03) : 746 - 754
  • [9] In Vivo Dog Intestinal Precipitation of Mebendazole: A Basic BCS Class II Drug
    Carlert, Sara
    Akesson, Pernilla
    Jerndal, Gunilla
    Lindfors, Lennart
    Lennernas, Hans
    Abrahamsson, Bertil
    MOLECULAR PHARMACEUTICS, 2012, 9 (10) : 2903 - 2911
  • [10] BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide
    Markovic, Milica
    Zur, Moran
    Ragatsky, Inna
    Cvijic, Sandra
    Dahan, Arik
    PHARMACEUTICS, 2020, 12 (12) : 1 - 16